antiplatelet agent

antiplatelet agent

[-plat′lit]
therapeutic agent that inhibits platelet function. Often employed to prevent clot propagation or secondary thrombosis in patients who have had a primary arterial thrombolytic event such as acute myocardial infarction, peripheral artery disease, or cerebrovascular accident.

antiplatelet agent

Therapeutics Any agent–eg, aspirin, that ↓ platelet clumping and clotting

an·ti·plate·let a·gent

(an'tē-plāt'lĕt ā'jĕnt)
Agent that inhibits platelet aggregation and thus reduces the risk of thrombus formation.
References in periodicals archive ?
It proposed a clinical response to Clopidogrel, an oral, thienopyridine-class antiplatelet agent used to inhibit blood clots in coronary artery disease.
Daiichi Sankyo Company, Limited today announced that it has launched the antiplatelet agent EfientA 3.
Just as Sanofi-Aventis lost exclusivity for its blockbuster drug Plavix (clopidogrel), the Food and Drug Administration approved several generic formulations of the antiplatelet agent
1) Aspirin, a salicylate, is the most commonly used over-the-counter (OTC) antiplatelet agent, taken at either an 81 mg dose for cardioprevention or a full-strength dose of 325 mg.
There are no clinical trials demonstrating that changing from one antiplatelet agent to another, or increasing the dose, following a TIA or stroke is beneficial in reducing recurrence.
26] However, clopidogrel is the main antiplatelet agent associated with drug-eluting stent thrombosis when withdrawn.
One investigation that would assist in the management of these patients is an accurate contemporaneous assessment of the effect of the antiplatelet agent on their platelet function.
5% of residents with a history of stroke were not receiving an anticoagulant or antiplatelet agent.
and 21 other companies manufacturing the antiplatelet agent about its adverse side effects and instructed them to add a warning on documents accompanying the product, ministry officials said.
announced that it has received approval from the Ministry of Health, Labor and Welfare in Japan for the antiplatelet agent Efient 3.
On Thursday, February 13, 2014, Medicines announced that the FDA Cardiovascular and Renal Drugs Advisory Committee (CRDAC) has voted to recommend against approval of the intravenous antiplatelet agent Cangrelor for use in patients undergoing percutaneous coronary intervention (PCI) -- or cardiac stent procedures -- or those that require bridging from oral antiplatelet therapy to surgery.